Low-density lipoprotein in the setting of congestive heart failure: Is lower really better? |
| |
Authors: | Tamara Horwich |
| |
Institution: | (1) Division of Cardiology, University of California, Los Angeles, 10833 Le Conte Avenue, CHS A2-237, Los Angeles, CA 90095, USA |
| |
Abstract: | Hypercholesterolemia is a risk factor for coronary artery disease (CAD), CAD mortality, and incident heart failure (HF). Lipid-lowering
therapy with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) has been shown to reduce the risk of developing
HF in patients with CAD. However, in patients with chronic established HF, hypercholesterolemia has not been associated with
an increased risk of mortality. Several studies have demonstrated that higher lipid and lipoprotein levels, including total
cholesterol, low-density lipoprotein, high-density lipoprotein, and triglycerides, are associated with significantly improved
outcomes in HF of both ischemic and nonischemic etiologies. In light of the association between high cholesterol levels and
improved survival in HF, statin or other lipid-lowering therapy in HF remains controversial. To date, large outcome trials
of statin therapy in HF of multiple etiologies have not demonstrated mortality benefit. |
| |
Keywords: | |
本文献已被 SpringerLink 等数据库收录! |
|